Kohlberg Kravis Roberts & Co’s Transphorm, Inc. Common Stock TGAN Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio TGAN Stock Details TGAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-24,411,968	Closed	-$120M	–	71
2024 Q1	$120M	Hold	24,411,968	–	–	3.09%	6
2023 Q4	$89.1M	Hold	24,411,968	–	–	2.63%	9
2023 Q3	$54.2M	Buy	24,411,968 +1,735,988	+8%	+$4.85M	1.9%	11
2023 Q2	$77.1M	Hold	22,675,980	–	–	2.39%	9
2023 Q1	$90.5M	Hold	22,675,980	–	–	2.72%	8
2022 Q4	$123M	Hold	22,675,980	–	–	4.16%	8
2022 Q3	$114M	Hold	22,675,980	–	–	2.29%	10
2022 Q2	$86.4M	Buy	22,675,980 +500,000	+2%	+$3.19M	1.15%	10
2022 Q1	$157M	Buy	+22,175,980	New	+$156M	1.42%	10

Kohlberg Kravis Roberts & Co's TGAN Position: Q2 2024 in Review

Kohlberg Kravis Roberts & Co sold out of Transphorm, Inc. Common Stock (TGAN) in Q2 2024, closing a stake of 24,411,968 shares — an estimated $120M sold.

Kohlberg Kravis Roberts & Co first reported a position in TGAN in Q1 2022 and held it in 9 quarters. The position peaked at $157M in Q1 2022. 0 funds tracked by Wall St. Rank hold TGAN as of Q2 2024.

Kohlberg Kravis Roberts & Co reported no remaining Transphorm, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Kohlberg Kravis Roberts & Co sold 24,411,968 Transphorm, Inc. Common Stock shares in Q2 2024, an estimated $120M.
Kohlberg Kravis Roberts & Co first reported a position in Transphorm, Inc. Common Stock in Q1 2022 and held it in 9 quarters.
Kohlberg Kravis Roberts & Co's Transphorm, Inc. Common Stock position peaked at $157M in Q1 2022.
0 funds tracked by Wall St. Rank held Transphorm, Inc. Common Stock as of Q2 2024.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q2 2024, filed 14 Aug 2024.